Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 684.35

+1.4%

12:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CuttingEdge Bio who wrote (2876)	3/27/2020 10:16:57 AM
From: Miljenko Zuanic	of 3557

OT:VIR (and relevant to REGN) My point is that they went after sera-Abs from recovered subjects (my guess, who were severe ill), with some modification which will complicate production, so it is up to their capability for selection and to study assays. They do not have gene-sequencing capability (as REGN) to correlate those assays data with mutations on virus itself (I am not sure can REGN run those genetic sequencing on live-viruses????)! BIIB action will be telling!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next